Psychological impact of the COVID-19 pandemic for patients with epilepsy: A systematic review and meta-analysis

2021 ◽  
Vol 124 ◽  
pp. 108340
Author(s):  
Naoto Kuroda ◽  
Takafumi Kubota
2019 ◽  
Vol 13 ◽  
Author(s):  
Kai-Ge Liang ◽  
Rong-Zheng Mu ◽  
Yu Liu ◽  
Dan Jiang ◽  
Tian-Tian Jia ◽  
...  

2006 ◽  
Vol 5 (1) ◽  
pp. 61-75 ◽  
Author(s):  
Dejana Braithwaite ◽  
Jon Emery ◽  
Fiona Walter ◽  
A. Toby Prevost ◽  
Stephen Sutton

2021 ◽  
Author(s):  
Chen qi Zhang ◽  
◽  
Xueyang Bai ◽  
Yong Wan ◽  
Hongyan Li ◽  
...  

Review question / Objective: We aim to systematically examine and compare the efficacy, safety and retention rate of ER divalproex (VPA-ER) and conventional DR divalproex (VPA-DR) on patients with epilepsy. Condition being studied: To our knowledge, comparison and conversion studies about VPA-ER and conventional VPA-DR are lacked. Small-sample studies analyzing the safety and efficacy of VPA-ER in different populations remain controversial. Therefore, this study aims to systematically review the safety, efficacy and retention rate of VPA-ER and VPA-DR by meta-analysis.


2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Bereket Duko ◽  
Mohammed Ayalew ◽  
Alemayehu Toma

Abstract Background Headache is the symptom of pain in the face, head or neck that causes disability in most people with medical and neurological disorders. It frequently co-occurs with most chronic diseases such as epilepsy and significantly impacts the quality of life. However, epidemiologic data from different studies showed different rates of prevalence. Therefore, we conducted this review to summarize the available epidemiologic evidence on the topic and formulate recommendations for future research and clinical practice. Methods We followed the preferred reporting items for systematic review and meta-analysis (PRISMA) guidelines. We systematically searched the literature using popular databases such as PubMed, EMBASE, Psych-INFO, and SCOPUS. We further scanned the reference lists of the eligible studies to supplement our electronic search. The Comprehensive Meta-Analysis software version 3.0 (CMA 3.0) was used to conduct a meta-analysis. Subgroup and sensitivity analysis were performed and Cochran’s Q- and the I2- test were used to assess the source of heterogeneity. The funnel plot and Egger’s regression tests were used to assess potential publication bias. Results A total of 17 studies conducted both in developed and developing countries including 5564 study participants were combined in this meta-analysis. The pooled estimated prevalence of headache among patients with epilepsy was 48.4%. The pooled estimated prevalence of Inter-Ictal headache (IIH) (42.2%) and Postictal headache (PIH) (43.1%) were higher when compared to tension-type headache (TTH) (26.2%), migraine with aura (26.0%) and migraine without aura (10.4%). The pooled prevalence of headache was 50.6% and 49.5% for developed and developing countries respectively. The pooled prevalence of headache among patients with epilepsy was considerably higher among females (63.0%) when compared to males (33.3%). Moreover, the pooled estimated prevalence of headache among patients with epilepsy was ranging from 46.0% to 52.2% in a leave-one-out sensitivity analysis. Conclusion The pooled estimated prevalence of headache among patients with epilepsy was considerably high (48.4%). Screening and appropriate management of headaches among patients with epilepsy are warranted.


2021 ◽  
Vol 11 (3) ◽  
pp. 392
Author(s):  
Pablo Cabezudo-García ◽  
Natalia Mena-Vázquez ◽  
Nicolás L. Ciano-Petersen ◽  
Guillermina García-Martín ◽  
Guillermo Estivill-Torrús ◽  
...  

Background: The prevalence of neural autoantibodies in epilepsy of unknown etiology varies among studies. We aimed to conduct a systematic review and meta-analysis to determine the pooled global prevalence and the prevalence for each antibody. Methods: A systematic search was conducted for studies that included prospectively patients ≥16 years old with epilepsy of unknown etiology and systematically determined neural autoantibodies. A meta-analysis was undertaken to estimate pooled prevalence in total patients with a positive result for at least one neural autoantibody in serum and/or cerebrospinal fluid (CSF) and for each autoantibody. Results: Ten of the eleven studies that met the inclusion criteria and a total of 1302 patients with epilepsy of unknown etiology were included in themeta-analysis. The global pooled prevalence (IC95%) was 7.6% (4.6–11.2) in a total of 82 patients with a positive result for any neural autoantibody. None of the controls available in the studies had a positive result. Individual pooled prevalence for each autoantibody was: glycine receptor (GlyR) (3.2%), glutamic acid decarboxylase (GAD) (1.9%), N-methyl-d-aspartate receptor (NMDAR) (1.8%), leucine-rich glioma inactivated-1 protein (LGI1) (1.1%), contactin-2-associated protein (CASPR2) (0.6%) and onconeuronal (0.2%). Conclusions: The pooled prevalence of neural autoantibodies in patients with epilepsy of unknown etiology is small but not irrelevant. None of the controls had a positive result. There was high heterogeneity among studies. In the future, a homogeneous protocol for testing neural autoantibodies is recommended.


2004 ◽  
Vol 96 (2) ◽  
pp. 122-133 ◽  
Author(s):  
D. Braithwaite ◽  
J. Emery ◽  
F. Walter ◽  
A. T. Prevost ◽  
S. Sutton

Sign in / Sign up

Export Citation Format

Share Document